Iloprost treatment for refractory Raynaud's phenomenon in two infants

Clinical and Experimental Rheumatology

Volumn 26, Issue 3 SUPPL. 49, 2008, Pages

  Shouval, Dror S ^a   Mukamel, Masza ^a,b   Zulian, Francesco ^c   Amir, Jacob ^a   Harel, Liora ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Children; Iloprost; Ischemic digits; Prostaglandin; Raynaud's phenomenon

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DOUBLE STRANDED DNA ANTIBODY; GLYCERYL TRINITRATE; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE;

ABSENCE OF SIDE EFFECTS; ANTIBODY TITER; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; CYANOSIS; DISEASE DURATION; DISEASE RESISTANCE; DOPPLER FLOWMETRY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; FEMALE; FINGER BLOOD FLOW; GANGRENE; HUMAN; MALE; MUTATIONAL ANALYSIS; PALLOR; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RAYNAUD PHENOMENON;

FEMALE; FINGERS; HUMANS; ILOPROST; INFANT; MALE; NECROSIS; RAYNAUD DISEASE; VASODILATOR AGENTS;

EID: 52049120846     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. SILMAN A, HOLLIGAN S, BRENNAN P, MADDISON P: Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 1990; 301: 590-2.
2. WIGLEY FM: Clinical practice. Raynaud's phenomenon. N Engl J Med 2002; 347: 1001-8.
3. JONES GT, HERRICK AL, WOODHAM SE, BAILDAM EM, MACFARLANE GJ, SILMAN AJ: Occurrence of Raynaud's phenomenon in children ages 12-15 years: Prevalence and association with other common symptoms. Arhritis Rheum 2003; 48: 3518-21.
4. NIGROVIC PA, FUHLBRIGGE RC, SUNDEL RP: Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics 2003; 111: 715-21.
5. DUFFY CM, LAXER RM, LEE P, RAMSAY C, FRITZLER M, SILVERMAN ED: Raynaud syndrome in childhood. J Pediatr 1989; 114: 73-8.
6. CLIFFORD BD, DONAHUE D, SMITH L et al.: High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-9.
7. FRANSSILA R, HEDMAN K: Infection and musculoskeletal conditions: Viral causes of arthritis. Best Pract Res Clin Rheumatol 2006; 20: 1139-57.
8. HOFFMAN GS, FRANCK WA: Infectious mononucleosis, autoimmunity, and vasculitis. A case report. JAMA 1979; 241: 2735-6.
9. DOHERTY M, BRADFIELD JW: Polyarteritis nodosa associated with acute cytomegalovirus infection. Ann Rheum Dis 1981; 40: 419-21.
10. HAREL L, STRAUSSBERG R, RUDICH H, COHEN AH, AMIR J: Raynaud's phenomenon as a manifestation of parvovirus B19 infection: Case reports and review of parvovirus B19 rheumatic and vasculitic syndromes. Clin Infect Dis 2000; 30: 500-3.
11. CALABRESE LH: Vasculitis and infection with the human immunodeficiency virus. Rheum Dis Clin North Am 1991; 17: 131-47.
12. LANGEVITZ P, BUSKILA D, LEE P, UROWITZ MB: Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE, infusions. J. Rheumatol 1989; 16: 1433-5.
13. KYLE MV, BELCHER G, HAZLEMAN BL: Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992; 19: 1403-6.
14. ZULIAN F, CORONA F, GERLONI V et al..: Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxford) 2004; 43: 229-33.
15. ZULIAN F, COSTANTINI C, MONTESCO MC, SCHIAVON F, ZACCHELLO F: Successful treatment of gangrene in systemic necrotizing vasculitis with iloprost. Br J Rheumatol 1998; 37: 228-30.